Ranitidine Injection USP 150mg/6ml Taj Pharma

  1. Name of the medicinal product

Ranitidine Injection USP 25mg/1ml Taj Pharma
Ranitidine Injection USP 50mg/2ml Taj Pharma
Ranitidine Injection USP 150mg/6ml Taj Pharma

  1. Qualitative and quantitative composition

a)Ranitidine Injection USP 25mg/1ml Taj Pharma
Each ml contains:
Ranitidine as Ranitidine hydrochloride
is equivalent to                                      25mg
Phenol                                                     5mg
Dibasic Potassium phosphate as buffer

b)Ranitidine Injection USP 50mg/2ml Taj Pharma
Each ml contains:
Ranitidine as Ranitidine hydrochloride
is equivalent to                                      25mg
Phenol                                                     5mg
Dibasic Potassium phosphate as buffer

c)Ranitidine Injection USP 150mg/6ml Taj Pharma
Each ml contains:
Ranitidine as Ranitidine hydrochloride
is equivalent to                                      25mg
Phenol                                                     5mg
Dibasic Potassium phosphate as buffer

For the full list of excipients, see section 6.1.

  1. Pharmaceutical form

Injection

Colourless to almost colourless clear liquid.

  1. Clinical particulars

4.1 Therapeutic indications

Ranitidine Injection is indicated in treatment benign gastric and duodenal ulceration including reflux oesophagitis, post operative ulcers and other conditions where reduction of gastric acid output is beneficial: prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients, the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers and in patients before general anaesthesia considered to be at risk of acid aspiration (Mendelson’s Syndrome), particularly obstetric patients during labour. Ranitidine is also indicated in Zollinger – Ellison Syndrome

Paediatric population (6 months to 18 years)

– Short term treatment of peptic ulcer

– Treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.

4.2 Posology and method of administration

Posology

Adults (including older people) / Adolescents (12 years and over)

Ranitidine Solution for Injection may be given at a dose of 50mg either as slow intravenous injection, intermittent intravenous infusion or intramuscularly.

Slow intravenous injection:

50mg diluted to a volume of 20ml and given over at least a period of 2 minutes which may be repeated every 6 to 8 hours.

Intermittent intravenous infusion:

25mg per hour for 2 hours; may be repeated 6 to 8 hours.

Intramuscular injection:

50mg (2ml) every six to eight hours.

Parenteral administration for the prophylaxis of haemorrhage from stress ulceration in seriously ill patients or the prophylaxis of recurrent haemorrhage in patients bleeding from peptic ulceration may be continued until oral feedings commences. Patients considered at risk requiring further treatment may then be transferred to treatment with ranitidine tablets.

For prophylaxis of upper gastro-intestinal haemorrhage from stress ulceration in seriously ill patients it may be preferable to give a priming dose of 50mg by slow intravenous injection followed by a continuous intravenous infusion of 0.125 – 0.25mg/kg/hr.

In patients considered to be at risk of developing acid aspiration syndrome, ranitidine 50mg may be given 45-60 minutes before induction of general anaesthesia either intramuscularly or by slow intravenous injection (over at least 2 minutes).

Older people

Normal dosage (as per adults) is recommended except in patients who have moderate to severe renal impairment.

Paediatric population

Children/infants (6 months to 11 years):

See Section 5.2 Pharmacokinetic Properties – Special Patient Populations.

Ranitidine Injection may be given as a slow (over 2 minutes) i.v. injection up to a maximum of 50mg every 6 to 8 hours.

Neonates (under 1 month)

See Section 5.2. Pharmacokinetic Properties – Special Patient Populations.

Peptic Ulcer Acute Treatment and Gastro-Oesophageal Reflux

Intravenous therapy in children with peptic ulcer disease is indicated only when oral therapy is not possible.

For acute treatment of peptic ulcer disease and gastro-oesophageal reflux in paediatric patients, Ranitidine injection may be administered at doses that have been shown to be effective for these diseases in adults and effective for acid suppression in critically ill children. The initial dose (2.0 mg/kg or 2.5 mg/kg, maximum 50 mg) may be administered as a slow intravenous infusion over 10 minutes, either with a syringe pump followed by a 3 mL flush with normal saline over 5 min, or following dilution with normal saline to 20 mL. Maintenance of pH > 4.0 can be achieved by intermittent infusion of 1.5 mg/kg every 6 h to 8 h. Alternatively treatment can be continuous, administering a loading dose of 0.45 mg/kg followed by a continuous infusion of 0.15 mg/kg/hr.

Prophylaxis of stress ulceration in seriously ill patients

The recommended dose for prophylaxis of stress ulceration is 1mg/kg (maximum 50 mg) every 6h to 8h.

Alternatively treatment can be continuous, administering 125 – 250 micrograms/kg/hr as continuous infusion.

Renal Impairment

Accumulation of ranitidine with resulting elevated plasma concentrations will occur in patients with severe renal impairment (creatinine clearance less than 50 ml/min). Accordingly, it is recommended in such patients that ranitidine be administered in doses of 25 mg.

Method of administration

Intravenous or intramuscular injection.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Treatment with a histamine H2 antagonist may mask the symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition. Where gastric ulcer is suspected, the possibility of malignancy should be excluded before therapy with Ranitidine Solution for injection is started.

Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with renal impairment. The dosage should be adjusted as detailed above in section 4.2.

Bradycardia in association with rapid administration of Ranitidine Solution for injection has been reported rarely, usually in patients with factors predisposing to cardiac rhythm disturbances. Recommended rates of administration should not be exceeded.

It has been reported that the use of higher than recommended doses of intravenous H2– antagonists has been associated with rises in liver enzymes when treatment has been extended beyond five days.

Although clinical reports of acute intermittent porphyria associated with ranitidine administration have been rare and inconclusive, ranitidine should be avoided in patients with a history of this condition.

In patients such as the elderly, persons with chronic lung disease, diabetes or the immunocompromised, there may be an increased risk of developing community acquired pneumonia. A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk increase of 1.82 (95% CI 1,26 – 2,64).

Post marketing data indicate reversible mental confusion, depression, and hallucinations have been reported most frequently in severely ill and elderly patients (see section 4.8).

4.5 Interaction with other medicinal products and other forms of interaction

Ranitidine has the potential to affect the absorption, metabolism or renal excretion of other drugs. The altered pharmacokinetics may necessitate dosage adjustment of the affected drug or discontinuation of treatment.

Interactions occur by several mechanisms including:

1) Inhibition of cytochrome P450-linked mixed function oxygenase system:

Ranitidine at usual therapeutic doses does not potentiate the actions of drugs which are inactivated by this enzyme system such as diazepam, lidocaine, phenytoin, propranolol and theophylline.

There have been reports of altered prothrombin time with coumarin anticoagulants (e.g. warfarin). Due to the narrow therapeutic index, close monitoring of increased or decreased prothrombin time is recommended during concurrent treatment with ranitidine.

2) Competition for renal tubular secretion:

Since ranitidine is partially eliminated by the cationic system, it may affect the clearance of other drugs eliminated by this route. High doses of ranitidine (e.g. such as those used in the treatment of Zollinger-Ellison syndrome) may reduce the excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs.

3) Alteration of gastric pH:

The bioavailability of certain drugs may be affected. This can result in either an increase in absorption (e.g. triazolam, midazolam, glipizide) or a decrease in absorption (e.g. ketoconazole, atazanavir, delaviridine, gefitnib).

4.6 Fertility, pregnancy and lactation

Pregnancy

Ranitidine crosses the placenta but therapeutic doses administered to obstetric patients in labour or undergoing caesarean section have been without any adverse effect on labour, delivery or subsequent neonatal progress.

Like other drugs ranitidine should only be used during pregnancy if considered essential by a physician.

Breast-feeding

Ranitidine is also excreted in human breast milk. Like other drugs ranitidine should only be used during nursing if considered essential.

Fertility

There are no data on the effects of ranitidine on human fertility. There were no effects on male and female fertility in animal studies.

4.7 Effects on ability to drive and use machines

Ranitidine Injection has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

The following convention has been utilised for the classification of undesirable effects:

very common (≥ 1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). Adverse event frequencies have been estimated from spontaneous reports from postmarketing data.

Blood & Lymphatic System Disorders

Very Rare: Blood count changes (leucopenia, thrombocytopenia). These are usually reversible. Agranulocytosis or pancytopenia, sometimes with marrow hypoplasia or marrow aplasia.

Immune System Disorders

Rare: Hypersensitivity reactions (urticaria, angioneurotic oedema, fever, bronchospasm, hypotension and chest pain).

Very Rare: Anaphylactic shock

These events have been reported after a single dose.

Psychiatric Disorders

Very Rare: Reversible mental confusion, depression and hallucinations.

These have been reported predominantly in severely ill and elderly patients.

Nervous System Disorders

Very Rare: Headache (sometimes severe), dizziness and reversible involuntary movement disorders.

Eye Disorders

Very Rare: Reversible blurred vision.

There have been reports of blurred vision, which is suggestive of a change in accommodation.

Cardiac Disorders

Very Rare: As with other H2 receptor antagonists bradycardia, A-V block and asystole (injection only).

Vascular Disorders

Very Rare: Vasculitis.

Gastrointestinal Disorders

Uncommon: Abdominal pain, constipation, nausea (these symptoms mostly improved during continued treatment).

Very Rare: Acute pancreatitis, diarrhoea

Hepatobiliary Disorders

Rare: Transient and reversible changes in liver function tests.

Very Rare: Hepatitis (hepatocellular, hepatocanalicular or mixed) with or without jaundice, these were usually reversible.

Skin and Subcutaneous Tissue Disorders

Rare: Skin rash.

Very Rare: Erythema multiforme, alopecia.

Musculoskeletal and Connective Tissue Disorders

Very Rare: Musculoskeletal symptoms such as arthralgia and myalgia.

Renal and urinary disorders

Rare: Elevation of plasma creatinine (usually slight; normalised during continued treatment).

Very rare: acute interstitial nephritis.

Reproductive System and Breast Disorders

Very Rare: Reversible impotence, breast symptoms and breast conditions (such as gynaecomastia and galactorrhoea)

Paediatric population

The safety of ranitidine has been assessed in children aged 0 to 16 years with acid-related disease and was generally well tolerated with an adverse event profile resembling that in adults. There are limited long term safety data available, in particular regarding growth and development.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important.

4.9 Overdose

Symptoms

Ranitidine is very specific in action and no particular problems are expected following overdosage with ranitidine formulations.

Management

Symptomatic and supportive therapy should be given as appropriate. Ranitidine may be removed by haemodialysis.

  1. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: H2 receptor antagonists

Mechanism of action

Ranitidine is specific, rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume, the acid and pepsin content of the secretion.

The clinical data available mentions the use of ranitidine in children to prevent stress ulcers. No direct evidence for prevention of stress ulcers is available. Treatment for these patients is based on the observation that pH is above 4 after administration of ranitidine. The value of this surrogate parameter in children with stress ulcers remains to be established.

5.2 Pharmacokinetic properties

Absorption

Peak plasma concentration is rapid and usually achieved within 15 minutes following intramuscular injection.

Distribution

Rantidine is not extensively bound to plasma proteins (15%), but exhibits a large volume of distribution ranging from 96 to 142 L.

Biotransformation

Ranitidine is not extensively metabolised. The fraction of the dose recovered as metabolites is similar after both oral and i.v dosing; and includes 6% of the dose in urine as the N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and 1 to 2% as the furoic acid analogue.

Elimination

Plasma concentrations decline bi-exponentially, with a terminal half-life of 2-3 hours. The major route of elimination is renal. After IV administration of 150 mg 3H- ranitidine, 98% of the dose was recovered, including 5% in faeces and 93% in urine, of which 70% was unchanged parent drug. After oral administration of 150 mg 3H- ranitidine, 96% of the dose was recovered, 26% in faeces and 70% in urine of which 35% was unchanged parent drug. Less than 3% of the dose is excreted in bile. Renal clearance is approximately 500mL/min, which exceeds glomerular filtration indicating net renal tubular secretion.

Special Patient Populations

Children/infants (6 months and above)

Limited pharmacokinetic data show that there were no significant differences in half-life (range for children 3 years and above: 1.7 – 2.2 h) and plasma clearance (range for children 3 years and above: 9 – 22 ml/min/kg) between children and healthy adults receiving intravenous ranitidine when correction is made for body weight. Pharmacokinetic data in infants is extremely limited but appears to be in line with that for older children.

Patients over 50 years of age

In patients over 50 years of age, half life is prolonged (3-4h) and clearance is reduced, consistent with the age-related decline of renal function. However, systemic exposure and accumulation are 50% higher. This difference exceeds the effect of declining renal function, and indicates increased bioavailability in older patients.

Paediatric population

Neonates (under 1 month)

Limited pharmacokinetic data from term babies undergoing treatment with Extracorporeal Membrane Oxygenation (EMCO) suggests that plasma clearance following iv administration may be reduced (1.5-8.2 ml/min/kg) and the half-life increased in the new-born. Clearance of ranitidine appeared to be related to the estimated glomerular filtration rate in the neonates.

5.3 Preclinical safety data

Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development.

  1. Pharmaceutical particulars

6.1 List of excipients

Sodium chloride

Monopotassium phosphate

Anhydrous disodium phosphate

Water for Injection

Nitrogen

6.2 Incompatibilities

Ranitidine 50mg in 2 ml solution for injection should not be mixed with any other medicinal products.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Do not store above 25°C. Do not freeze.

Keep the container in the outer carton in order to protect from light.

6.5 Nature and contents of container

Type I clear glass ampoules

Pack size: 2ml x 5 ampoules

6.6 Special precautions for disposal and other handling

Ranitidine 50mg/2ml Solution for injection may be diluted with Sodium Chloride intravenous infusion (0.9%). If stored incorrectly discolouration of the solution may occur.

Injection should not be autoclaved.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

 

7.Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com

Ranitidine Injection USP 25mg/1ml Taj Pharma
Ranitidine Injection USP 50mg/2ml Taj Pharma
Ranitidine Injection USP 150mg/6ml Taj Pharma

Package leaflet: Information for the user

Ranitidine hydrochloride

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or nurse.
  • If you get any side effects talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

The name of this medicine is Ranitidine 50mg/2ml Solution for Injection and Infusion (referred to as Ranitidine Injection throughout this leaflet).

What is in this leaflet:

1 What Ranitidine Injection is and what it is used for
2. What you need to know before you have Ranitidine Injection
3. How to have Ranitidine Injection
4. Possible side effects
5. How to store Ranitidine Injection
6. Contents of the pack and other information

  1. What ranitidine injection is and what it is used for

Ranitidine Injection is a solution for injection or infusion into a vein, or injection into a muscle. It contains ranitidine as the active substance.

Ranitidine is one of a group of medicines called H2-antagonists that lowers the amount of acid in your stomach.

It is used in adults (including the elderly) to:

  • Heal and stop ulcers of the stomach or duodenum (the stomach empties into this part of the intestine)
  • Improve problems caused by acid in the food pipe (oesophagus) or too much acid in the stomach. Both of these can cause pain or discomfort sometimes known as ‘indigestion’, ‘dyspepsia’ or ‘heartburn’
  • Stop ulcers from bleeding
  • Stop acid coming up from the stomach while under anaesthetic during an operation.

It is used in children (6 months to 18 years) to:

  • Heal ulcers in the stomach, or part of the gut that it empties into (the duodenum)
  • Heal and stop problems caused by acid in the food pipe (oesophagus) or too much acid in the stomach. Both of these can cause pain or discomfort sometimes known as “indigestion”, “dyspepsia” or “heartburn”.
  1. What you need to know before you have ranitidine injection

Do not have Ranitidine Injection:

  • if you are allergic to ranitidine or to any of the other ingredients in this medicine (listed in Section 6).

If you are not sure talk to your doctor or pharmacist before having Ranitidine Injection.

Warnings and precautions

Talk to your doctor or pharmacist before having Ranitidine Injection:

  • If you have stomach cancer
  • If you have kidney problems. You will need to have a different amount of Ranitidine Injection.
  • If you have a heart problem or a history of heart trouble
  • If you have a rare condition called acute porphyria
  • If you have had stomach ulcers before
  • If you are over 65 years old
  • If you have lung disease
  • If you are diabetic
  • If you have problems with your immune system

If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before having this medicine.

Other medicines and Ranitidine Injection

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines that you buy without a prescription and herbal medicines. This is because ranitidine can affect the way some other medicines work. Also some other medicines can affect the way ranitidine works.

In particular tell your doctor or pharmacist if you are taking any of the following medicines:

  • lidocaine, a local anaesthetic
  • anticoagulants (such as warfarin), used to thin the blood
  • propranolol, procainamide or n-acetylprocainamide, for heart problems
  • diazepam, for worry or anxiety problems
  • phenytoin, for epilepsy
  • theophylline, for breathing problems (asthma)
  • glipizide, for lowering blood glucose
  • atazanavir or delaviridine, for treating HIV infection
  • gefitnib for lung cancer
  • ketoconazole for fungal infections or thrush
  • triazolam for insomnia.

Midazolam may also be given before an operation. Tell your doctor you are taking ranitidine before you have an operation in case he or she wants to give you midazolam.

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before having Ranitidine Injection.

Pregnancy and breast-feeding

If you are pregnant, might become pregnant or breast-feeding you should not be given this medicine unless your doctor advises it is essential.

Ask your doctor, pharmacist or nurse for advice before taking any medicine, if you are pregnant or breast-feeding.

Driving and using machines

Ranitidine Injection is unlikely to affect your ability to drive or operate machinery

Ranitidine Injection contains Sodium and Potassium

Ranitidine Injection contains less than 1 mmol sodium (23 mg) per 50 mg, i.e. essentially sodium-free.

Ranitidine Injection contains less than 1mmol potassium (39mg) per 50mg, i.e. essentially potassium-free

  1. How to have ranitidine injection

You will never be expected to give yourself this medicine. It will always be given to you by someone who is trained to do so.

Your doctor will decide the correct dose of Ranitidine Injection for you.

Adults (including the elderly) and adolescents (12 years and older): This can be given by the doctor or nurse in one of three ways:

  • As a single injection into a muscle
  • As a slow infusion into a vein. This is where the drug is slowly given to you over a few minutes
  • As a continuous infusion into a vein. This is where the drug is slowly given to you over a few hours.

The recommended dose for an adult (including the elderly) and adolescents (12 years and older) is 50 mg every 6 to 8 hours, as a single injection into a muscle.

Different doses may also be given to you as a slow infusion or continuous infusion, depending on what condition you are being treated for.

Children and infants (6 months to 11 years): The dose will be given by a slow injection into a vein. The maximum dose is 50mg every 6 or 8 hours. It is usually only given if your child is unable to take ranitidine by mouth.

Kidney disease: If your kidneys are not working properly your doctor may give you a lower dose.

Your doctor or nurse will give you Ranitidine Injection so it is unlikely that you will receive too much. If you think that the effect of Ranitidine Injection is too strong or too weak or you have missed a dose, talk to your doctor or nurse. If you have any further questions on the use of this product, ask your doctor or nurse.

  1. Possible side effects

Like all medicines, Ranitidine Injection can cause side effects, although not everybody gets them.

Serious side effects

If any of the following happen, tell your doctor or nurse immediately as you may need urgent medical attention:

  • Allergic reactions, the signs may include:
  • Severe itching of the skin, rash or hives on the skin
  • Swelling of the hands, feet, ankles, face, lips, tongue, mouth or throat, which may cause difficulties in swallowing or breathing.
  • Swelling on other parts of the body
  • Chest pain, shortness of breath, wheezing or having trouble breathing
  • Unexpected fever and feeling faint especially when standing up
  • Kidney problems which can lead to back pain, fever, pain when passing urine, blood in the urine and changes in blood tests
  • Severe stomach pains, this may be a sign of something called ‘pancreatitis’
  • An irregular heartbeat either slower or faster than normal
  • Collapse

Other side effects

Tell your doctor at your next visit if you notice any of the following:

Uncommon: may affect up to 1 in 100 people

    • Stomach pain
    • Constipation
  • Feeling sick (nausea).

Rare side effects that may show up in blood tests:

  • Increase of serum creatinine in blood (kidney function test)
  • Changes to liver function

Check with your doctor as soon as possible if you notice any of the following:

  • Very rare: may affect up to 1 in 10,000 people
  • Depression
  • Confusion, hallucinations (seeing or hearing unexplained things)
  • Blood changes that may result in unusual tiredness, shortness of breath, being more likely to get infections bruising more easily
  • Uncontrolled movements
  • Your small blood vessels can become swollen (known as vasculitis). Signs of this can include: a rash, swollen joints or kidney problems
  • Headaches (sometimes severe)
  • Diarrhoea
  • Feeling dizzy or having blurred vision
  • Your liver can become swollen. This can lead to nausea (feeling sick) or vomiting (being sick), loss of appetite or generally feeling unwell, itching, fever, yellowing of the skin and eyes or dark coloured urine
  • Red blotches or lumps on the skin that may look like targets, unexplained hair loss
  • Your joints or muscles are painful and swollen
  • If you are a man, sexual impotence (this is normally reversible), tenderness of the breast, breast discharge and/or breast enlargement.

Reporting of side effects

If you get any side effects talk to your doctor or nurse.

  1. How to store ranitidine injection

Do not store above 25°C.

Keep ampoules in the carton to protect them from light.

Keep this medicine out of the sight and reach of children.

Ranitidine Injection should not be used after the expiry date which is stated on the ampoule and carton. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

  1. Further information

What Ranitidine Injection contains

The active substance is ranitidine. One 2ml ampoule contains 50mg of ranitidine as ranitidine hydrochloride.

Other ingredients are sodium chloride, potassium dihydrogen phosphate, disodium hydrogen phosphate dihydrate and water for injections.

What Ranitidine Injection looks like and contents of the pack

Ranitidine Injection is a clear, colourless liquid in amber glass ampoules.

Each carton of Ranitidine Injection contains 5 ampoules.

7.Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com

Related Products

Taj Generics (Taj Pharma) provides a wide range of products to the Indian market, including an extensive range of generics and specialty products; Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. Our Generics portfolio offers over 1500 products in the major therapeutic areas of gastro-intestinal, cardiovascular, pain management, oncology, anti-infectives, paediatrics and dermatology.